Aerpio Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
CINCINNATI--(BUSINESS WIRE)--Sep 24, 2018--Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Monday, October 1, 2018 at 10:40 a.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business update.
The presentation will be webcast live and may be accessed by visiting Aerpio’s website at http://ir.aerpio.com/.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company’s lead compound, AKB-9778, is a small molecule activator of the Tie2 pathway and is in clinical development for the treatment of non-proliferative diabetic retinopathy. For more information, please visit www.aerpio.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180924005069/en/
CONTACT: Investor & Media:
Aerpio Pharmaceuticals, Inc.
Chief Financial Officer
Burns McClellan, on behalf of Aerpio Pharmaceuticals, Inc.
Robert Flamm, Ph.D.
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK OHIO
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL DIABETES FDA
SOURCE: Aerpio Pharmaceuticals, Inc.
Copyright Business Wire 2018.
PUB: 09/24/2018 07:00 AM/DISC: 09/24/2018 07:01 AM